Oncology Clinical Trials and Research
Patients who qualify have access at Smilow Cancer Hospital's Greenwich Hospital Campus to national clinical trials and research focusing on the latest treatment protocols and medications.
Research studies as of April 2016
What are Clinical Trials?
ECOG-ACRIN E4112: Prospective Trial of MRI and Gene Expression Assay (Oncotype) in Ductal Carcinoma in Situ (DCIS). Principal Investigator Beverly Drucker, MD.
NCIC MA.32: Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Center. Principal Investigator, Beverly Drucker, MD.
ASBrS NSMR: American Society of Breast Surgeons Nipple Sparing Mastectomy Registry. Principal Investigator Barbara Ward, MD.
Yale HIC #1112009465: Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults. Principal Investigator Beverly Drucker, MD.
ECOG E1Z11: A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms. Principal Investigator Beverly Drucker, MD.
SWOG S1207: Phase III Randomized Trial Evaluating the Use of Adjuvant Endocrine Therapy with One Year of Everolimus or Placebo in Patients with Hormone Receptor-Positive and Her2/neu Negative Breast Cancer. Principal Investigator Beverly Drucker, MD.
TARGIT-US: A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery. Principal Investigator Daniela Gidea-Addeo, MD.
SWOG S0820: Phase III Trial Preventing Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer Using Eflornithine or Placebo and or Sulindac or Placebo. Principal Investigator Beverly Drucker, MD.
A1511216 ALCHEMIST: Adjuvant Lung Cancer Enrichment Marker and Sequencing Trial for Patients with Resectable or Resected Lung Cancer. Principal Investigator Beverly Drucker, MD.
A081105: Phase III Trial of Erlotinib or Placebo in Patients with Completely Resected EGFR Mutant Non-Small Cell Lung Cancer. Principal Investigator Beverly Drucker, MD.
E4512: Phase III Trial of Crizotinib or Placebo with Early Stage Completely Resected Tumors Harboring ALK Fusion Protein in Non-Small Cell Lung Cancer Patients. Principal Investigator Beverly Drucker, MD.
ECOG E1505: Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for patients with Completely Resected Stage IB-IIIA NSCLC. Principal Investigator, Beverly Drucker, MD.
Lung Cancer Screening
I-ELCAP (International Early Lung Cancer Action Program) Lung Cancer Screening Trial Using Low Dose CT Scans. The study’s main objective is to learn whether the identification and early diagnosis of lung cancer leads to improvement in survival. For more information about the I-ELCAP study at Greenwich Hospital call 203-863-3760 or visit ielcap.org. Principal Investigator David Mullen, MD.
SWOG S1314: A Randomized Phase II Trial of Co-Expression (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer. Principal Investigator Daniel Petrylak, MD.
A031201: Phase III Trial of Enzalutamide Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer. Principal Investigator Daniel Petrylak, MD.
HIC1402013489: Studying the Effects of Radiation Therapy (Xofigo) on the Immune System in Metastatic Prostate Cancer. Principal Investigator Daniel Petrylak, MD.
SWOG S1216: Phase III Randomized Trial Comparing Androgen Deprivation Therapy (ADT) + TAK-700 with ADT + Bicalutamide in Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer. Principal Investigator Daniel Petrylak, MD
NCI-9671: Exceptional Responders Pilot Studying the Molecular Profiling of Tumors from Patients Who are Exceptional Responders. Principal Investigator Ashwatha Narayana, MD
Greenwich Hospital is a member of the national clinical research group Southwest Oncology Group (SWOG) enabling patients who qualify access to phase II and phase III clinical trials. Greenwich Hospital also participates in clinical trials initiated by the Yale Cancer Center. SWOG is sponsored by the National Cancer Institute. For more information about SWOG, visit www.swog.org.
For more information
Contact clinical trials coordinators at 203-863-3760.